• 목록

Professor Weon Kuu Chung of Kyung Hee University Hospital at Gangdong

Founds READYCURE, Developing a Dementia Treatment System HeLaXON

On the 10th, READYCURE, a startup developing a digital X-ray treatment system specifically for 

dementia, announced that it secured Pre-A series funding from FuturePlay. 

The investment amount remains undisclosed.

Founded in October 2021, READYCURE is a research-based startup co-founded by 

Professor Weon Kuu Chung, a radiation oncologist at Kyung Hee University Hospital at Gangdong, 

along with neuroscientists and medical device experts.

Dr. Chung, a veteran with 27 years of experience and a radiation oncology specialization 

from Chonbuk National University Medical School, founded READYCURE by 

leveraging his seven years of experience in preclinical and clinical studies focused on 

 low-dose radiation therapy for dementia patients.

READYCURE is currently developing HeLaXON, a dementia treatment system that 

leverages digital X-rays to restore immune function in the brain. 

This approach contrasts sharply with the current global pharmaceutical giants 

investing vast sums in antibody treatments for dementia, 

focusing on cognitive decline prevention and treatment.

READYCURE is simultaneously conducting preclinical research to assess the efficacy of 

digital X-rays and multi-center, patient-blind, randomized clinical trials on the largest scale of 

Alzheimer's-type dementia patients using a cancer treatment machine. 

Significant interim results have been observed, affirming READYCURE's unique therapeutic 

approach. HeLaXON is designed as a safe and economical dementia treatment device with no side effects, 

incorporating software-based personalized treatment methods.

READYCURE CEO Dr. Weon Kuu Chung stated, “While recent dementia drugs achieve 

a 27% disease progression delay, HeLaXON has shown up to an 80% improvement. 

We aim to establish a new paradigm in dementia treatment through a drug-free, 

innovative system that will transform the medical field."

Koo Yong-seok, lead investment manager at FuturePlay, commented, 

“We decided to invest in READYCURE due to the outstanding cognitive improvement 

effects observed in clinical results and the robust preclinical findings, which highlight the 

potential of this pioneering treatment approach."